Physician profile
Sheetal Patel
NPI 1255693529
$4,550.47
in general payments reported to CMS, 2019-2025
30 companies · $691 in 2025
The $691 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $850 · 2020: $473 · 2021: $960 · 2022: $320 · 2023: $416 · 2024: $842 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $584.12 | 2022-2025 | Diamondback Peripheral, Assurity, Esprit |
| Abiomed | $573.82 | 2023-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $462.93 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $424.36 | 2019-2024 | Farxiga, Brilinta |
| Amgen INC. | $415.67 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $282.46 | 2019 | |
| Zimmer Biomet Holdings, INC. | $257.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $236.61 | 2020-2025 | |
| Boston Scientific Corporation | $224.26 | 2024-2025 | Watchman Flx, Avvigo Guidance System, Opticross |
| Medtronic, INC. | $145.54 | 2021-2025 | Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $140.99 | 2019-2024 | Camzyos |
| Penumbra, INC. | $123.89 | 2022 | |
| Pfizer INC. | $95.92 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $92.43 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.89 | 2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $55.13 | 2019 | |
| Amarin Pharma, INC. | $50.22 | 2019-2020 | |
| Inari Medical, INC. | $38.79 | 2021 | |
| Cardiovascular Systems INC. | $38.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.58 | 2021-2023 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $31.56 | 2024 | |
| Chiesi USA, INC. | $30.40 | 2021-2024 | Cleviprex, Kengreal |
| Flowphysix INC | $25.86 | 2025 | Flowrunner |
| Shockwave Medical, INC | $25.64 | 2021 | |
| Scpharmaceuticals INC. | $19.12 | 2025 | |
| Alnylam Pharmaceuticals INC. | $19.03 | 2023 | Onpattro |
| Cvrx, INC. | $18.23 | 2023 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $16.87 | 2024 | Assure Wcd |
| Angiodynamics, INC. | $13.80 | 2025 | Auryon Laser System 100-120 Vac |
| Kowa Pharmaceuticals America, INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.